Literature DB >> 23873794

β3-Adrenergic receptor antagonist improves exercise performance in pacing-induced heart failure.

Satoshi Masutani1, Heng-Jie Cheng, Atsushi Morimoto, Hiroshi Hasegawa, Qing-Hua Han, William C Little, Che Ping Cheng.   

Abstract

In heart failure (HF), the impaired left ventricular (LV) arterial coupling and diastolic dysfunction present at rest are exacerbated during exercise. We have previously shown that in HF at rest stimulation of β3-adrenergic receptors by endogenous catecholamine depresses LV contraction and relaxation. β3-Adrenergic receptors are activated at higher concentrations of catecholamine. Thus exercise may cause increased stimulation of cardiac β3-adrenergic receptors and contribute to this abnormal response. We assessed the effect of L-748,337 (50 μg/kg iv), a selective β3-adrenergic receptor antagonist (β3-ANT), on LV dynamics during exercise in 12 chronically instrumented dogs with pacing-induced HF. Compared with HF at rest, exercise increased LV end-systolic pressure (PES), minimum LV pressure (LVPmin), and the time constant of LV relaxation (τ) with an upward shift of early diastolic portion of LV pressure-volume loop. LV contractility decreased and arterial elastance (EA) increased. LV arterial coupling (EES/EA) (0.40 vs. 0.51) was impaired. Compared with exercise in HF preparation, exercise after β3-ANT caused similar increases in heart rate and PES but significantly decreased τ (34.9 vs. 38.3 ms) and LVPmin with a downward shift of the early diastolic portion of LV pressure-volume loop and further augmented dV/dtmax. Both EES and EES/EA (0.68 vs. 0.40) were increased. LV mechanical efficiency improved from 0.39 to 0.53. In conclusion, after HF, β3-ANT improves LV diastolic filling; increases LV contractility, LV arterial coupling, and mechanical efficiency; and improves exercise performance.

Entities:  

Keywords:  congestive heart failure; pressure-volume relation; β-adrenergic receptor blockers

Mesh:

Substances:

Year:  2013        PMID: 23873794      PMCID: PMC3761346          DOI: 10.1152/ajpheart.00371.2012

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  66 in total

1.  A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure.

Authors:  Eric J Eichhorn; Michael J Domanski; Heidi Krause-Steinrauf; Michael R Bristow; Philip W Lavori
Journal:  N Engl J Med       Date:  2001-05-31       Impact factor: 91.245

Review 2.  Place of beta 3-adrenoceptors among other beta-adrenoceptor subtypes in the regulation of the cardiovascular system.

Authors:  B Rozec; J Noireaud; J N Trochu; C Gauthier
Journal:  Arch Mal Coeur Vaiss       Date:  2003-09

3.  Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study.

Authors:  Viviane M Conraads; Marco Metra; Otto Kamp; Gilles W De Keulenaer; Burkert Pieske; José Zamorano; Panos E Vardas; Michael Böhm; Livio Dei Cas
Journal:  Eur J Heart Fail       Date:  2011-12-06       Impact factor: 15.534

4.  Adrenergic control of the force-frequency and relaxation-frequency relations in patients with hypertrophic cardiomyopathy.

Authors:  H Izawa; M Yokota; Y Takeichi; M Inagaki; K Nagata; M Iwase; T Sobue
Journal:  Circulation       Date:  1997-11-04       Impact factor: 29.690

5.  Levosimendan improves LV systolic and diastolic performance at rest and during exercise after heart failure.

Authors:  Hideo Tachibana; Heng-Jie Cheng; Tomohiko Ukai; Akihiko Igawa; Zhu-Shan Zhang; William C Little; Che-Ping Cheng
Journal:  Am J Physiol Heart Circ Physiol       Date:  2004-10-14       Impact factor: 4.733

6.  Chronic blocking of beta 3-adrenoceptor ameliorates cardiac function in rat model of heart failure.

Authors:  Run-tao Gan; Wei-min Li; Chun-hong Xiu; Jing-xia Shen; Xu Wang; Shuang Wu; Yi-hui Kong
Journal:  Chin Med J (Engl)       Date:  2007-12-20       Impact factor: 2.628

7.  Effect of exercise on left ventricular-arterial coupling assessed in the pressure-volume plane.

Authors:  W C Little; C P Cheng
Journal:  Am J Physiol       Date:  1993-05

8.  Diastolic properties of the normal left ventricle during supine exercise.

Authors:  H Nonogi; O M Hess; M Ritter; H P Krayenbuehl
Journal:  Br Heart J       Date:  1988-07

Review 9.  What is the role of beta-adrenergic signaling in heart failure?

Authors:  Martin J Lohse; Stefan Engelhardt; Thomas Eschenhagen
Journal:  Circ Res       Date:  2003-11-14       Impact factor: 17.367

10.  Rabbit, a relevant model for the study of cardiac beta 3-adrenoceptors.

Authors:  Leslie Audigane; Benoît-Gilles Kerfant; Aziza El Harchi; Ilka Lorenzen-Schmidt; Gilles Toumaniantz; Anne Cantereau; Daniel Potreau; Flavien Charpentier; Jacques Noireaud; Chantal Gauthier
Journal:  Exp Physiol       Date:  2009-01-16       Impact factor: 2.969

View more
  6 in total

1.  The crosstalk of HDAC3, microRNA-18a and ADRB3 in the progression of heart failure.

Authors:  Jingtao Na; Haifeng Jin; Xin Wang; Kan Huang; Shuang Sun; Qiang Li; Wenting Zhang
Journal:  Cell Biosci       Date:  2021-02-06       Impact factor: 7.133

2.  Activation of human brown adipose tissue by a β3-adrenergic receptor agonist.

Authors:  Aaron M Cypess; Lauren S Weiner; Carla Roberts-Toler; Elisa Franquet Elía; Skyler H Kessler; Peter A Kahn; Jeffrey English; Kelly Chatman; Sunia A Trauger; Alessandro Doria; Gerald M Kolodny
Journal:  Cell Metab       Date:  2015-01-06       Impact factor: 27.287

3.  Role of the β3-adrenergic receptor subtype in catecholamine-induced myocardial remodeling.

Authors:  Gizem Kayki Mutlu; Ebru Arioglu Inan; Irem Karaomerlioglu; V Melih Altan; Nilgun Yersal; Petek Korkusuz; Marcella Rocchetti; Antonio Zaza
Journal:  Mol Cell Biochem       Date:  2018-01-23       Impact factor: 3.396

Review 4.  Healthful aging mediated by inhibition of oxidative stress.

Authors:  Stephen F Vatner; Jie Zhang; Marko Oydanich; Tolga Berkman; Rotem Naftalovich; Dorothy E Vatner
Journal:  Ageing Res Rev       Date:  2020-10-19       Impact factor: 10.895

Review 5.  Targeting β3-Adrenergic Receptors in the Heart: Selective Agonism and β-Blockade.

Authors:  Alessandro Cannavo; Walter J Koch
Journal:  J Cardiovasc Pharmacol       Date:  2017-02       Impact factor: 3.105

6.  Anti-obesity and metabolic efficacy of the β3-adrenergic agonist, CL316243, in mice at thermoneutrality compared to 22°C.

Authors:  Cuiying Xiao; Margalit Goldgof; Oksana Gavrilova; Marc L Reitman
Journal:  Obesity (Silver Spring)       Date:  2015-06-05       Impact factor: 5.002

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.